# PRKAR1A

Source: https://onco.cc/targets/prkar1a/  
OnCo record `prkar1a` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.

## Summary

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.85, affected pathway 0.83, literature 0.86, genetic association 0.01, somatic mutation 0.85, animal model 0.73). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Adrenocortical Carcinoma, Medulloblastoma, Pilocytic Astrocytoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein kinase cAMP-dependent type I regulatory subunit alpha; cAMP-dependent protein kinase type I-alpha regulatory subunit; CNC1; PRKAR1; TSE1; PKR1; Prkar1alpha
- Tags: cancer-genes-wave
- Symbol: PRKAR1A
- Class: tumor-suppressor
- Biology: Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells. Location: Cell membrane (UniProt). Locus 17q24.2 (HGNC).
- Where found: Adrenocortical carcinoma: IntOGen driver in 1 cohort (ACC); Thyroid cancer: Open Targets association 0.54 with thyroid cancer (MONDO_0002108); Renal cell carcinoma: Open Targets association 0.52 with renal cell carcinoma (MONDO_0005086); Medulloblastoma: IntOGen driver in 2 cohorts (MBL); Paediatric low-grade glioma: IntOGen driver in 1 cohort (PAST)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Melanotic Neurilemmoma.

## Sources

- HGNC HGNC:9388: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9388
- UniProt P10644: https://www.uniprot.org/uniprotkb/P10644/entry
- NCBI Gene 5573: https://www.ncbi.nlm.nih.gov/gene/5573
- Ensembl ENSG00000108946: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108946

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Adrenocortical carcinoma](https://onco.cc/cancers/adrenocortical/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/), [Paediatric low-grade glioma](https://onco.cc/cancers/paediatric-low-grade-glioma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)

---
JSON: https://onco.cc/api/v1/entities/prkar1a.json